A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
Status:
Recruiting
Trial end date:
2023-04-22
Target enrollment:
Participant gender:
Summary
Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches
between Humira® and ABP 501 (new high concentration formulation) compared with continued use
of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study
is composed of two periods: A lead-in period of treatment with Humira® followed by a
randomized two parallel arm period.